A San Francisco startup is testing a brain implant that could turn cancer monitoring into something closer to a live data feed.
Coherence Neuro said its coin-sized device was temporarily placed in the brains of three people undergoing tumor-removal surgery at Royal Melbourne Hospital in Australia. The implant stayed in place for about 30 minutes before being removed, giving the company an early safety check before any longer-term human implantation.
The device is a brain-computer interface built to detect the electrical signals associated with tumors and deliver mild electrical stimulation. Coherence says the approach is aimed first at glioblastoma, an aggressive brain cancer that often returns after surgery.
Ben Woodington, the company’s chief executive and co-founder, described the idea as treating tumors partly through their electrical behavior. “These are electrical conditions, just like epilepsy, just like depression. This is a network problem in the brain,” he said.
The approach challenges the usual rhythm of brain cancer care. Patients with glioblastoma typically receive MRI scans every two to three months, while Coherence wants its implant to continuously monitor disease activity and help doctors adjust treatment remotely through a connected app.
The company’s design includes 16 threads that extend into brain tissue from an implant seated in the skull. It is intended to be inserted during tumor resection surgery, when doctors are already operating to remove cancerous tissue.
Early results suggest the test was limited but important: the device was used briefly in consenting patients, not left in place permanently. Coherence plans to begin a trial next year in which glioblastoma patients would receive long-term implants.
The development could affect a field where patients still face few options after diagnosis. For now, the device has cleared only its first short human test, and the next question is whether continuous monitoring and stimulation can help when tumors return.
